{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:33:22Z","timestamp":1793414002651,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11010-020-03965-7","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T16:07:28Z","timestamp":1605110848000},"page":"993-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease"],"prefix":"10.1007","volume":"476","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-4898","authenticated-orcid":false,"given":"Tewodros","family":"Shibabaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"issue":"21","key":"3965_CR1","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.CIR.0000038493.65177.94","volume":"106","author":"PM Kris-Etherton","year":"2002","unstructured":"Kris-Etherton PM, Harris WS, Appel LJ (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106(21):2747\u20132757","journal-title":"Circulation"},{"issue":"1","key":"3965_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2007.11.008","volume":"197","author":"WS Harris","year":"2008","unstructured":"Harris WS et al (2008) Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197(1):12\u201324","journal-title":"Atherosclerosis"},{"issue":"3","key":"3965_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.15232\/S1080-7446(15)30713-0","volume":"25","author":"DL Palmquist","year":"2009","unstructured":"Palmquist DL (2009) Omega-3 fatty acids in metabolism, health, and nutrition and for modified animal product foods. Prof Ani Sci 25(3):207\u2013249","journal-title":"Prof Ani Sci"},{"issue":"5","key":"3965_CR4","doi-asserted-by":"publisher","first-page":"1645S","DOI":"10.1093\/ajcn\/65.5.1645S","volume":"65","author":"WS Harris","year":"1997","unstructured":"Harris WS (1997) n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65(5):1645S\u20131654S","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"3965_CR5","first-page":"116","volume":"1","author":"MJ Calvo","year":"2017","unstructured":"Calvo MJ et al (2017) Omega-3 polyunsaturated fatty acids and cardiovascular health: a molecular view into structure and function. Vessel Plus 1(3):116\u2013128","journal-title":"Vessel Plus"},{"key":"3965_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/2045125319858901","volume":"9","author":"A Reimers","year":"2019","unstructured":"Reimers A, Ljung H (2019) The emerging role of omega-3 fatty acids as a therapeutic option in neuropsychiatric disorders. Therap Adv Psychopharmacol 9:2045125319858901","journal-title":"Therap Adv Psychopharmacol"},{"key":"3965_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-food-111317-095850","volume":"9","author":"F Shahidi","year":"2018","unstructured":"Shahidi F, Ambigaipalan P (2018) Omega-3 polyunsaturated fatty acids and their health benefits. Annu Rev Food Sci Technol 9:345\u2013381","journal-title":"Annu Rev Food Sci Technol"},{"issue":"5","key":"3965_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1042\/BST20160474","volume":"45","author":"PC Calder","year":"2017","unstructured":"Calder PC (2017) Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans 45(5):1105\u20131115","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"3965_CR9","first-page":"6","volume":"13","author":"A Mohebi-Nejad","year":"2014","unstructured":"Mohebi-Nejad A, Bikdeli B (2014) Omega-3 supplements and cardiovascular diseases. Tanaffos 13(1):6","journal-title":"Tanaffos"},{"key":"3965_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev.nutr.25.051804.101917","volume":"25","author":"H Sampath","year":"2005","unstructured":"Sampath H, Ntambi JM (2005) Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 25:317\u2013340","journal-title":"Annu Rev Nutr"},{"issue":"11","key":"3965_CR11","first-page":"681","volume":"38","author":"JC Bradberry","year":"2013","unstructured":"Bradberry JC, Hilleman DE (2013) Overview of omega-3 fatty acid therapies. Pharm Ther 38(11):681","journal-title":"Pharm Ther"},{"issue":"9","key":"3965_CR12","doi-asserted-by":"publisher","first-page":"1746S","DOI":"10.1093\/jn\/138.9.1746S","volume":"138","author":"PM Kris-Etherton","year":"2008","unstructured":"Kris-Etherton PM et al (2008) The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. J Nutr 138(9):1746S\u20131751S","journal-title":"J Nutr"},{"key":"3965_CR13","first-page":"40","volume":"1","author":"Y Xu","year":"2014","unstructured":"Xu Y et al (2014) Is the jury still out on the benefits of fish, seal and flax oils in cardiovascular disease. Ann Nutr Disord Ther 1:40","journal-title":"Ann Nutr Disord Ther"},{"issue":"4","key":"3965_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbalip.2014.08.010","volume":"1851","author":"PC Calder","year":"2015","unstructured":"Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochimica et Biophysica Acta (BBA) Mol Cell Biol Lipids 1851(4):469\u2013484","journal-title":"Biochimica et Biophysica Acta (BBA) Mol Cell Biol Lipids"},{"issue":"1","key":"3965_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/B:MCBI.0000041863.11248.8d","volume":"263","author":"DJ Holub","year":"2004","unstructured":"Holub DJ, Holub BJ (2004) Omega-3 fatty acids from fish oils and cardiovascular disease. Mol Cell Biochem 263(1):217\u2013225","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"3965_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/clp.15.1","volume":"10","author":"NA Shaikh","year":"2015","unstructured":"Shaikh NA, Tappia PS (2015) Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease? Clin Lipidol 10(1):27\u201332","journal-title":"Clin Lipidol"},{"issue":"1","key":"3965_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/nu11010046","volume":"11","author":"MA Gammone","year":"2019","unstructured":"Gammone MA et al (2019) Omega-3 polyunsaturated fatty acids: benefits and endpoints in sport. Nutrients 11(1):46","journal-title":"Nutrients"},{"issue":"6","key":"3965_CR18","doi-asserted-by":"publisher","first-page":"1981S","DOI":"10.1093\/ajcn\/87.6.1981S","volume":"87","author":"TA Jacobson","year":"2008","unstructured":"Jacobson TA (2008) Role of n\u2212 3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 87(6):1981S\u20131990S","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"3965_CR19","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","volume":"140","author":"AC Skulas-Ray","year":"2019","unstructured":"Skulas-Ray AC et al (2019) Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 140(12):e673\u2013e691","journal-title":"Circulation"},{"key":"3965_CR20","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program (US). Expert Panel on Detection, & Treatment of High Blood Cholesterol in Adults (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (No. 2). National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health","DOI":"10.1001\/jama.285.19.2486"},{"issue":"5","key":"3965_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40256-014-0090-3","volume":"14","author":"HA Blair","year":"2014","unstructured":"Blair HA, Dhillon S (2014) Omega-3 carboxylic acids (epanova\u00ae): a review of its use in patients with severe hypertriglyceridemia. Am J Cardiovasc Drugs 14(5):393\u2013400","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9567","key":"3965_CR22","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M et al (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369(9567):1090\u20131098","journal-title":"Lancet"},{"issue":"1","key":"3965_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11883-019-0762-1","volume":"21","author":"RP Mason","year":"2019","unstructured":"Mason RP (2019) New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep 21(1):2","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"3965_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jnutbio.2009.12.004","volume":"21","author":"Y Adkins","year":"2010","unstructured":"Adkins Y, Kelley DS (2010) Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 21(9):781\u2013792","journal-title":"J Nutr Biochem"},{"issue":"1","key":"3965_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13059","volume":"288","author":"A Langsted","year":"2020","unstructured":"Langsted A, Madsen CM, Nordestgaard BG (2020) Contribution of remnant cholesterol to cardiovascular risk. J Intern Med 288(1):116\u2013127","journal-title":"J Intern Med"},{"issue":"3","key":"3965_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/clc.22692","volume":"40","author":"DL Bhatt","year":"2017","unstructured":"Bhatt DL et al (2017) Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl\u2013intervention trial. Clin Cardiol 40(3):138\u2013148","journal-title":"Clin Cardiol"},{"issue":"6","key":"3965_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40256-014-0099-7","volume":"14","author":"ES Kim","year":"2014","unstructured":"Kim ES, McCormack PL (2014) Icosapent ethyl: a review of its use in severe hypertriglyceridemia. Am J Cardiovasc Drugs 14(6):471\u2013478","journal-title":"Am J Cardiovasc Drugs"},{"issue":"16","key":"3965_CR28","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","volume":"102","author":"FM Sacks","year":"2000","unstructured":"Sacks FM et al (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102(16):1886\u20131892","journal-title":"Circulation"},{"issue":"1-3","key":"3965_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1388-1981(00)00151-7","volume":"1529","author":"S Kang","year":"2000","unstructured":"Kang S, Davis RA (2000) Cholesterol and hepatic lipoprotein assembly and secretion. Biochimica et Biophysica Acta (BBA) Mol Cell Biol Lipids 1529(1-3):223\u2013230","journal-title":"Biochimica et Biophysica Acta (BBA) Mol Cell Biol Lipids"},{"issue":"1","key":"3965_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/MOL.0000000000000146","volume":"26","author":"FM Sacks","year":"2015","unstructured":"Sacks FM (2015) The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol 26(1):56","journal-title":"Curr Opin Lipidol"},{"key":"3965_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","volume":"267","author":"A Wolska","year":"2017","unstructured":"Wolska A et al (2017) Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis 267:49\u201360","journal-title":"Atherosclerosis"},{"issue":"3","key":"3965_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.numecd.2017.11.001","volume":"28","author":"M Arca","year":"2018","unstructured":"Arca M et al (2018) Hypertriglyceridemia and omega-3 fatty acids: their often overlooked role in cardiovascular disease prevention. Nutr Metab Cardiovasc Dis 28(3):197\u2013205","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"3965_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1586\/14779072.6.3.391","volume":"6","author":"HE Bays","year":"2008","unstructured":"Bays HE et al (2008) Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 6(3):391\u2013409","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"3965_CR34","first-page":"1","volume":"8","author":"M Alves-Bezerra","year":"2011","unstructured":"Alves-Bezerra M, Cohen DE (2011) Triglyceride metabolism in the liver. Compr Physiol 8(1):1\u201322","journal-title":"Compr Physiol"},{"key":"3965_CR35","unstructured":"Feingold KR, Grunfeld C (2018) Introduction to lipids and lipoproteins. In endotext [internet]. MDText. com, Inc"},{"key":"3965_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2018.11.006","volume":"281","author":"J Dittrich","year":"2019","unstructured":"Dittrich J et al (2019) Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease. Atherosclerosis 281:17\u201324","journal-title":"Atherosclerosis"},{"issue":"7","key":"3965_CR37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12325-009-0045-2","volume":"26","author":"H Rupp","year":"2009","unstructured":"Rupp H (2009) Omacor\u00ae(prescription omega-3-acid ethyl esters 90): from severe rhythm disorders to hypertriglyceridemia. Adv Ther 26(7):675","journal-title":"Adv Ther"},{"issue":"9943","key":"3965_CR38","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626\u2013635","journal-title":"Lancet"},{"issue":"3","key":"3965_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/17460875.2.3.263","volume":"2","author":"D Bhatnagar","year":"2007","unstructured":"Bhatnagar D, Hussain F (2007) Omega-3 fatty acid ethyl esters (Omacor\u00ae) for the treatment of hypertriglyceridemia. Futur Lipidol 2(3):263\u2013270","journal-title":"Futur Lipidol"},{"issue":"5","key":"3965_CR40","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jacl.2016.07.009","volume":"10","author":"S Th\u00e9riault","year":"2016","unstructured":"Th\u00e9riault S et al (2016) Frameshift mutation in the APOA5 gene causing hypertriglyceridemia in a Pakistani family: management and considerations for cardiovascular risk. J Clin Lipidol 10(5):1272\u20131277","journal-title":"J Clin Lipidol"},{"issue":"3","key":"3965_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3122\/jabfm.19.3.310","volume":"19","author":"RN Pejic","year":"2006","unstructured":"Pejic RN, Lee DT (2006) Hypertriglyceridemia. J Am Board Fam Med 19(3):310\u2013316","journal-title":"J Am Board Fam Med"},{"key":"3965_CR42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fendo.2020.00252","volume":"11","author":"CJ Packard","year":"2020","unstructured":"Packard CJ, Boren J, Taskinen MR (2020) Causes and consequences of hypertriglyceridemia. Front Endocrinol 11:252","journal-title":"Front Endocrinol"},{"issue":"49","key":"3965_CR43","first-page":"825","volume":"116","author":"KG Parhofer","year":"2019","unstructured":"Parhofer KG, Laufs U (2019) The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int 116(49):825","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"3965_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/0004563219827620","volume":"56","author":"LR Ruhaak","year":"2019","unstructured":"Ruhaak LR, van der Laarse A, Cobbaert CM (2019) Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Ann Clin Biochem 56(3):338","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"3965_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5551\/jat.11.6","volume":"11","author":"CJ Packard","year":"2004","unstructured":"Packard CJ, Saito Y (2004) Non\u2212 HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb 11(1):6\u201314","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"3965_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"S Paredes","year":"2019","unstructured":"Paredes S et al (2019) Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity. Sci Rep 9(1):1\u20137","journal-title":"Sci Rep"},{"issue":"2","key":"3965_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pathol.2018.11.006","volume":"51","author":"SS Carr","year":"2019","unstructured":"Carr SS et al (2019) Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology 51(2):148\u2013154","journal-title":"Pathology"},{"issue":"22","key":"3965_CR48","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.105.583336","volume":"112","author":"AD Sniderman","year":"2005","unstructured":"Sniderman AD (2005) Apolipoprotein B versus non\u2013high-density lipoprotein cholesterol: and the winner is. Circulation 112(22):3366\u20133367","journal-title":"Circulation"},{"issue":"22","key":"3965_CR49","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1161\/CIRCULATIONAHA.104.532499","volume":"112","author":"T Pischon","year":"2005","unstructured":"Pischon T et al (2005) Non\u2013high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112(22):3375\u20133383","journal-title":"Circulation"},{"issue":"7","key":"3965_CR50","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M et al (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51(7):724\u2013730","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"3965_CR51","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.amjcard.2007.11.046","volume":"101","author":"M Miller","year":"2008","unstructured":"Miller M, Ginsberg HN, Schaefer EJ (2008) Relative atherogenicity and predictive value of non\u2013high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 101(7):1003\u20131008","journal-title":"Am J Cardiol"},{"issue":"20","key":"3965_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009778","volume":"7","author":"JG Robinson","year":"2018","unstructured":"Robinson JG et al (2018) Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life. J Am Heart Assoc 7(20):e009778","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"3965_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/clinchem\/48.3.401","volume":"48","author":"PN Durrington","year":"2002","unstructured":"Durrington PN (2002) Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? Clin Chem 48(3):401\u2013402","journal-title":"Clin Chem"},{"issue":"12","key":"3965_CR54","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/jama.286.12.1468","volume":"286","author":"H Campos","year":"2001","unstructured":"Campos H et al (2001) Low-density lipoprotein size, pravastatin treatment, and coronary events. Jama 286(12):1468\u20131474","journal-title":"Jama"},{"issue":"1","key":"3965_CR55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12944-019-1166-5","volume":"18","author":"W Dai","year":"2019","unstructured":"Dai W et al (2019) Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease. Lipids Health Dis 18(1):220","journal-title":"Lipids Health Dis"},{"issue":"3","key":"3965_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/MOL.0000000000000502","volume":"29","author":"B Ramms","year":"2018","unstructured":"Ramms B, Gordts PL (2018) Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol 29(3):171\u2013179","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"3965_CR57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","volume":"114","author":"A Kawakami","year":"2006","unstructured":"Kawakami A et al (2006) Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 (VCAM-1) in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114(7):681\u2013687","journal-title":"Circulation"},{"key":"3965_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1155\/2018\/4721357","volume":"2018","author":"R Garg","year":"2018","unstructured":"Garg R, Rustagi T (2018) Management of hypertriglyceridemia induced acute pancreatitis. BioMed Res Int 2018:12","journal-title":"BioMed Res Int"},{"key":"3965_CR59","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2147\/DMSO.S188856","volume":"12","author":"E Shemesh","year":"2019","unstructured":"Shemesh E, Zafrir B (2019) Hypertriglyceridemia-related pancreatitis in patients with type 2 diabetes: links and risks. Diabetes Metab Syndr Obes Targets Ther 12:2041","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"2","key":"3965_CR60","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ajcn\/77.2.300","volume":"77","author":"DC Chan","year":"2003","unstructured":"Chan DC et al (2003) Randomized controlled trial of the effect of n\u20133 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 77(2):300\u2013307","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"3965_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12944-017-0541-3","volume":"16","author":"J Oscarsson","year":"2017","unstructured":"Oscarsson J, Hurt-Camejo E (2017) Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis 16(1):149","journal-title":"Lipids Health Dis"},{"issue":"10","key":"3965_CR62","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.bcp.2010.07.031","volume":"80","author":"N Tanaka","year":"2010","unstructured":"Tanaka N et al (2010) Eicosapentaenoic acid improves hepatic steatosis independent of PPAR\u03b1 activation through inhibition of SREBP-1 maturation in mice. Biochem Pharmacol 80(10):1601\u20131612","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"3965_CR63","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","volume":"26","author":"CW Kim","year":"2017","unstructured":"Kim CW et al (2017) Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab 26(2):394\u2013406","journal-title":"Cell Metab"},{"issue":"3","key":"3965_CR64","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1194\/jlr.M800383-JLR200","volume":"50","author":"YA Moon","year":"2009","unstructured":"Moon YA, Hammer RE, Horton JD (2009) Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J Lipid Res 50(3):412\u2013423","journal-title":"J Lipid Res"},{"issue":"7","key":"3965_CR65","doi-asserted-by":"publisher","first-page":"a004754","DOI":"10.1101\/cshperspect.a004754","volume":"3","author":"J Ye","year":"2011","unstructured":"Ye J, DeBose-Boyd RA (2011) Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol 3(7):a004754","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"3965_CR66","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt MJ et al (2019) The liver as an endocrine organ\u2014linking NAFLD and insulin resistance. Endocr Rev 40(5):1367\u20131393","journal-title":"Endocr Rev"},{"issue":"1","key":"3965_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00109-019-01863-0","volume":"98","author":"AD Khwairakpam","year":"2020","unstructured":"Khwairakpam AD et al (2020) The vital role of ATP citrate lyase in chronic diseases. J Mol Med 98(1):71\u201395","journal-title":"J Mol Med"},{"issue":"7710","key":"3965_CR68","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41586-018-0201-4","volume":"558","author":"M Hunkeler","year":"2018","unstructured":"Hunkeler M et al (2018) Structural basis for regulation of human acetyl-CoA carboxylase. Nature 558(7710):470\u2013474","journal-title":"Nature"},{"issue":"4","key":"3965_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.amjcard.2005.12.024","volume":"98","author":"MH Davidson","year":"2006","unstructured":"Davidson MH (2006) Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 98(4):27\u201333","journal-title":"Am J Cardiol"},{"issue":"6","key":"3965_CR70","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2146\/ajhp060164","volume":"64","author":"JM McKenney","year":"2007","unstructured":"McKenney JM, Sica D (2007) Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm 64(6):595\u2013605","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"3965_CR71","doi-asserted-by":"publisher","first-page":"8755","DOI":"10.1074\/jbc.R100062200","volume":"277","author":"J Jump","year":"2002","unstructured":"Jump J, D. B. (2002) The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277(11):8755\u20138758","journal-title":"J Biol Chem"},{"issue":"3","key":"3965_CR72","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1074\/jbc.M105711200","volume":"277","author":"T Yoshikawa","year":"2002","unstructured":"Yoshikawa T et al (2002) Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J Biol Chem 277(3):1705\u20131711","journal-title":"J Biol Chem"},{"issue":"4","key":"3965_CR73","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-0033-1358523","volume":"33","author":"X Xu","year":"2013","unstructured":"Xu X et al (2013) Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis 33(4):301. NIH Public Access","journal-title":"Semin Liver Dis"},{"issue":"4","key":"3965_CR74","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/01.mol.0000236363.63840.16","volume":"17","author":"WS Harris","year":"2006","unstructured":"Harris WS, Bulchandani D (2006) Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17(4):387\u2013393","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"3965_CR75","doi-asserted-by":"publisher","first-page":"349","DOI":"10.7150\/ijbs.16635","volume":"13","author":"D Li","year":"2017","unstructured":"Li D et al (2017) Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c. Int J Biol Sci 13(3):349","journal-title":"Int J Biol Sci"},{"issue":"9","key":"3965_CR76","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109(9):1125\u20131131","journal-title":"J Clin Invest"},{"issue":"36","key":"3965_CR77","doi-asserted-by":"publisher","first-page":"25892","DOI":"10.1074\/jbc.274.36.25892","volume":"274","author":"HJ Kim","year":"1999","unstructured":"Kim HJ, Takahashi M, Ezaki O (1999) Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver a possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 274(36):25892\u201325898","journal-title":"J Biol Chem"},{"key":"3965_CR78","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.25015","volume":"6","author":"S Rong","year":"2017","unstructured":"Rong S et al (2017) Expression of SREBP-1c requires SREBP-2-mediated generation of a sterol ligand for LXR in livers of mice. Elife 6:e25015","journal-title":"Elife"},{"issue":"26","key":"3965_CR79","doi-asserted-by":"publisher","first-page":"10791","DOI":"10.1074\/jbc.M116.747006","volume":"292","author":"N Tajima-Shirasaki","year":"2017","unstructured":"Tajima-Shirasaki N et al (2017) Eicosapentaenoic acid down-regulates expression of the selenoprotein P gene by inhibiting SREBP-1c protein independently of the AMP-activated protein kinase pathway in H4IIEC3 hepatocytes. J Biol Chem 292(26):10791\u201310800","journal-title":"J Biol Chem"},{"issue":"30","key":"3965_CR80","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.3748\/wjg.v22.i30.6757","volume":"22","author":"NM Sagar","year":"2016","unstructured":"Sagar NM et al (2016) Mechanisms of triglyceride metabolism in patients with bile acid diarrhea. World J Gastroenterol 22(30):6757","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3965_CR81","doi-asserted-by":"publisher","first-page":"E395","DOI":"10.1152\/ajpendo.00414.2001","volume":"282","author":"S Neschen","year":"2002","unstructured":"Neschen S et al (2002) Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content. Am J Physiol Endocrinol Metab 282(2):E395\u2013E401","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"3965_CR82","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/oby.2002.70","volume":"10","author":"C Chambrier","year":"2002","unstructured":"Chambrier C et al (2002) Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor \u03b3. Obes Res 10(6):518\u2013525","journal-title":"Obes Res"},{"issue":"8","key":"3965_CR83","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/1044549041562267","volume":"23","author":"A Zhao","year":"2004","unstructured":"Zhao A et al (2004) Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol 23(8):519\u2013526","journal-title":"DNA Cell Biol"},{"issue":"7","key":"3965_CR84","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/07853890.2018.1511919","volume":"50","author":"A Sahebkar","year":"2018","unstructured":"Sahebkar A et al (2018) Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Ann Med 50(7):565\u2013575","journal-title":"Ann Med"},{"issue":"15","key":"3965_CR85","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","volume":"135","author":"DS Siscovick","year":"2017","unstructured":"Siscovick DS et al (2017) Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 135(15):e867\u2013e884","journal-title":"Circulation"},{"issue":"1","key":"3965_CR86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jjcc.2015.08.002","volume":"67","author":"J Endo","year":"2016","unstructured":"Endo J, Arita M (2016) Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol 67(1):22\u201327","journal-title":"J Cardiol"},{"key":"3965_CR87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cbi.2019.04.037","volume":"308","author":"AM Darwesh","year":"2019","unstructured":"Darwesh AM et al (2019) Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system. Chem Biol Interact 308:20\u201344","journal-title":"Chem Biol Interact"},{"key":"3965_CR88","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fphar.2019.00205","volume":"10","author":"G Fredman","year":"2019","unstructured":"Fredman G (2019) Can inflammation-resolution provide clues to treat patients according to their plaque phenotype? Front Pharmacol 10:205","journal-title":"Front Pharmacol"},{"key":"3965_CR89","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fpsyt.2020.00122","volume":"11","author":"J Giacobbe","year":"2020","unstructured":"Giacobbe J et al (2020) The anti-inflammatory role of omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative and neurological disorders. Front Psych 11:122","journal-title":"Front Psych"},{"key":"3965_CR90","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molimm.2020.07.017","volume":"126","author":"F Wang","year":"2020","unstructured":"Wang F et al (2020) Specialized pro-resolving mediators: it\u2019s anti-oxidant stress role in multiple disease models. Mol Immunol 126:40\u201345","journal-title":"Mol Immunol"},{"issue":"13","key":"3965_CR91","first-page":"7442","volume":"24","author":"Q Li","year":"2020","unstructured":"Li Q et al (2020) Maresins: anti-inflammatory pro-resolving mediators with therapeutic potential. Eur Rev Med Pharmacol Sci 24(13):7442\u20137453","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"3965_CR92","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1365-2249.2005.02851.x","volume":"142","author":"SC Mills","year":"2005","unstructured":"Mills SC, Windsor AC, Knight SC (2005) The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes. Clin Exp Immunol 142(2):216\u2013228","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"3965_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/07315724.2002.10719248","volume":"21","author":"AP Simopoulos","year":"2002","unstructured":"Simopoulos AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21(6):495\u2013505","journal-title":"J Am Coll Nutr"},{"issue":"1-2","key":"3965_CR94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000109871","volume":"1","author":"M Massaro","year":"2008","unstructured":"Massaro M et al (2008) Omega\u20133 fatty acids, inflammation and angiogenesis: nutrigenomic effects as an explanation for anti-atherogenic and anti-inflammatory effects of fish and fish oils. Lifestyle Genomics 1(1-2):4\u201323","journal-title":"Lifestyle Genomics"},{"issue":"9","key":"3965_CR95","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.116.309492","volume":"119","author":"JR Viola","year":"2016","unstructured":"Viola JR et al (2016) Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ Res 119(9):1030\u20131038","journal-title":"Circ Res"},{"key":"3965_CR96","first-page":"972","volume":"119","author":"EB Thorp","year":"2016","unstructured":"Thorp EB (2016) Proresolving lipid mediators restore balance to the vulnerable plaque. Am Heart Assoc 119:972\u2013974","journal-title":"Am Heart Assoc"},{"issue":"9","key":"3965_CR97","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/carcin\/bgg110","volume":"24","author":"YY Fan","year":"2003","unstructured":"Fan YY et al (2003) Chemopreventive n-3 fatty acids activate RXR\u03b1 in colonocytes. Carcinogenesis 24(9):1541\u20131548","journal-title":"Carcinogenesis"},{"issue":"4","key":"3965_CR98","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.18632\/aging.101210","volume":"9","author":"AZ Lalia","year":"2017","unstructured":"Lalia AZ et al (2017) Influence of omega-3 fatty acids on skeletal muscle protein metabolism and mitochondrial bioenergetics in older adults. Aging (Albany NY) 9(4):1096","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"3965_CR99","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/nu2030355","volume":"2","author":"PC Calder","year":"2010","unstructured":"Calder PC (2010) Omega-3 fatty acids and inflammatory processes. Nutrients 2(3):355\u2013374","journal-title":"Nutrients"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-020-03965-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T14:10:23Z","timestamp":1669558223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-020-03965-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3965"],"URL":"https:\/\/doi.org\/10.1007\/s11010-020-03965-7","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"9 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that there is no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}